8-KOther EventsExhibits & Filings

GE HealthCare Technologies Inc. 8-K Report, Corporate Update (Sep 13, 2024)

Filed September 13, 2024For Securities:GEHC

Summary

GE HealthCare Technologies Inc. (GEHC) announced on September 12, 2024, the commencement and pricing of an underwritten offering of 15,000,000 shares of its common stock at $86.00 per share. It is crucial for investors to note that GEHC itself is not selling any shares and will not receive any proceeds from this offering or an associated debt-for-equity exchange. The shares being offered are currently held by GE Aerospace, which is expected to exchange them for its own indebtedness held by Morgan Stanley Bank, N.A. and Morgan Stanley Senior Funding, Inc. prior to the closing of the offering. Following this debt-for-equity exchange, Morgan Stanley & Co. LLC, acting as the selling stockholder, intends to sell these GEHC shares to the underwriters. This transaction primarily facilitates the divestiture of GE Aerospace's stake in GEHC and a debt reduction for GE Aerospace, without direct capital infusion into GEHC. Investors should monitor the completion of this offering and the subsequent market performance of GEHC shares.

Key Highlights

  • 1GEHC announced an underwritten offering of 15,000,000 shares of common stock at $86.00 per share.
  • 2GEHC will not receive any proceeds from the sale of these shares.
  • 3The shares are being sold by Morgan Stanley & Co. LLC, as the selling stockholder, after GE Aerospace exchanges them for its indebtedness.
  • 4This transaction is part of a debt-for-equity exchange involving GE Aerospace and Morgan Stanley.
  • 5Underwriters have been granted an option to purchase an additional 2,250,000 GEHC shares.
  • 6The offering involves GE Aerospace, Morgan Stanley, and Citigroup Global Markets Inc. as underwriters.

Frequently Asked Questions

No, GE HealthCare Technologies Inc. will not receive any proceeds from this offering. The shares are being sold by a third party (Morgan Stanley & Co. LLC, after acquiring them from GE Aerospace) and not by the company itself.

The shares are being sold by Morgan Stanley & Co. LLC, designated as the selling stockholder. These shares are expected to be acquired by Morgan Stanley through a debt-for-equity exchange with GE Aerospace prior to the sale.

The primary purpose appears to be for GE Aerospace to exchange its indebtedness for GE HealthCare shares and then for those shares to be sold into the market by Morgan Stanley. This facilitates GE Aerospace's deleveraging and divestiture of its stake in GE HealthCare.

The sale of a significant number of shares (up to 17.25 million including the option) by a selling stockholder could create downward pressure on the stock price due to increased supply. However, the impact will also depend on market demand and the overall market conditions at the time of the offering.